IsoPlexis, a Branford-based life science technology company, went public in early October, with its stock initially trading at $15 a share. The company’s stock is listed on the Nasdaq under the ticker symbol “ISO.”
IsoPlexis, which is headquartered at 35 NE Industrial Road in Branford, was founded by Yale students in 2013. It has developed technology that can help physicians develop personalized treatments for patients, including those with cancer and autoimmune diseases.
The company has also been involved in studying COVID-19 and how it interacts with the immune system.